Furthermore, a growing number of targeted therapies has been approved in more than one tumor type based on specific molecular alterations (e.g., BRAF, HER2/ERBB2, RET, BRCA1/2, PD-L1) including the approval of dabrafenib/trametinib for pediatric patients with BRAF V600E mutant glioma and selpercatinib, a selective kinase inhibitor for patients with rearranged during transfection (RET) fusion-positive tumor by 2023 [5, 15, 16]. Here, RET is linked to neoplasm.